Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRSNASDAQ:CPIXNASDAQ:EYENNASDAQ:NLNKNASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.45-0.3%$1.40$1.05▼$5.17$155.93M0.381.21 million shs402,410 shsCPIXCumberland Pharmaceuticals$3.15-7.6%$4.77$1.04▼$7.25$47.13M-0.39873,973 shs120,657 shsEYENEyenovia$15.96+51.1%$3.99$0.85▼$124.80$45.97M2.471.26 million shs4.63 million shsNLNKNewLink Genetics$9.07$0.82▼$3.60$162.00M1.17547,540 shsN/AONCYOncolytics Biotech$0.90+14.4%$0.55$0.33▼$1.53$86.73M1.07677,893 shs1.54 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%-1.70%-7.37%+3.21%+25.65%CPIXCumberland Pharmaceuticals0.00%+21.15%-41.67%-25.53%+105.88%EYENEyenovia0.00%+46.69%+408.28%+1,562.33%-74.03%NLNKNewLink Genetics0.00%0.00%0.00%0.00%+97.27%ONCYOncolytics Biotech0.00%+20.04%+170.73%+81.95%-10.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.4299 of 5 stars3.62.00.00.01.91.70.6CPIXCumberland Pharmaceuticals0.5758 of 5 stars0.03.00.00.02.11.70.0EYENEyenovia2.6258 of 5 stars3.05.00.00.03.00.00.6NLNKNewLink GeneticsN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech1.6912 of 5 stars3.43.00.00.02.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$9.71572.27% UpsideCPIXCumberland Pharmaceuticals 0.00N/AN/AN/AEYENEyenovia 2.00Hold$2.00-87.47% DownsideNLNKNewLink Genetics 0.00N/AN/AN/AONCYOncolytics Biotech 2.75Moderate Buy$4.33380.95% UpsideCurrent Analyst Ratings BreakdownLatest ONCY, CPIX, EYEN, ACRS, and NLNK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/23/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.005/28/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.005/21/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/16/2025ONCYOncolytics BiotechJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/14/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.005/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$17.78M8.80N/AN/A$1.44 per share1.00CPIXCumberland Pharmaceuticals$37.87M1.24$0.26 per share12.25$1.61 per share1.96EYENEyenovia$60K766.08N/AN/A($695.52) per share-0.02NLNKNewLink Genetics$940K0.00N/AN/A$2.11 per share0.00ONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)CPIXCumberland Pharmaceuticals-$6.48M-$0.25N/A∞N/A-7.98%6.92%2.33%8/5/2025 (Estimated)EYENEyenovia-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)NLNKNewLink Genetics-$42.99M-$1.03N/AN/AN/A-4,592.84%-41.50%-33.95%N/AONCYOncolytics Biotech-$23.14M-$0.29N/AN/AN/AN/A-313.77%-130.19%7/30/2025 (Estimated)Latest ONCY, CPIX, EYEN, ACRS, and NLNK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025EYENEyenovia-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/14/2025Q1 2025ONCYOncolytics Biotech-$0.09-$0.06+$0.03-$0.06N/AN/A5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A5/6/2025Q1 2025CPIXCumberland PharmaceuticalsN/A$0.15N/A$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/AEYENEyenoviaN/AN/AN/AN/AN/ANLNKNewLink GeneticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A5.065.06CPIXCumberland Pharmaceuticals0.181.251.09EYENEyenoviaN/A0.340.34NLNKNewLink GeneticsN/A7.987.98ONCYOncolytics BiotechN/A3.203.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CPIXCumberland Pharmaceuticals15.51%EYENEyenovia25.84%NLNKNewLink Genetics32.32%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%CPIXCumberland Pharmaceuticals44.85%EYENEyenovia7.10%NLNKNewLink Genetics12.70%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million101.35 millionOptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableEYENEyenovia402.88 million2.68 millionOptionableNLNKNewLink Genetics5537.33 millionN/ANot OptionableONCYOncolytics Biotech3094.28 million94.19 millionNot OptionableONCY, CPIX, EYEN, ACRS, and NLNK HeadlinesRecent News About These CompaniesOncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 5 at 4:19 AM | americanbankingnews.comOncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 5 at 4:14 AM | marketbeat.comOncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 5 at 4:14 AM | marketbeat.comOncolytics Biotech (NASDAQ:ONCY) Trading Down 3% - Should You Sell?July 1, 2025 | marketbeat.comOncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development StrategyJune 30, 2025 | prnewswire.comWith Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in OncologyJune 20, 2025 | newswire.caPrivate-Sector Oncology May Be the Market’s Best-Understood SecretJune 20, 2025 | baystreet.caUSA News Group: With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in OncologyJune 20, 2025 | finanznachrichten.deUSA News Group: Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is GoingJune 18, 2025 | finanznachrichten.deAfter Major Oncology Conference, All Eyes Turn to Industry InnovationJune 12, 2025 | prnewswire.co.ukPOncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy ProgramsJune 11, 2025 | prnewswire.comOncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation CapabilitiesMay 23, 2025 | prnewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Immunome (IMNM), Oncolytics Biotech (ONCY) and Hookipa Pharma (HOOK)May 18, 2025 | theglobeandmail.comJones Trading Downgrades Oncolytics Biotech (ONCY)May 17, 2025 | msn.comOncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical MomentumMay 17, 2025 | finanznachrichten.deOncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comOncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comOncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical MomentumMay 14, 2025 | prnewswire.comOncolytics Biotech to Discuss Q1 2025 Financial Results on May 14May 8, 2025 | tipranks.comOncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational HighlightsMay 6, 2025 | prnewswire.comOncolytics Biotech, Inc. Common Shares (ONCY) Latest After Hours TradesMay 4, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCY, CPIX, EYEN, ACRS, and NLNK Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.44 -0.01 (-0.34%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$1.44 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Cumberland Pharmaceuticals NASDAQ:CPIX$3.15 -0.26 (-7.62%) As of 07/3/2025 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Eyenovia NASDAQ:EYEN$15.96 +5.40 (+51.14%) Closing price 07/2/2025 07:59 PM EasternExtended Trading$15.96 0.00 (0.00%) As of 07/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.NewLink Genetics NASDAQ:NLNKNewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.Oncolytics Biotech NASDAQ:ONCY$0.90 +0.11 (+14.41%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.90 +0.00 (+0.44%) As of 07/3/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
